论文部分内容阅读
目的探讨EGFR和DEC1在肺腺癌中的表达及与临床特征的关系。方法采用免疫组织化学方法检测75例肺腺癌癌组织及癌旁组织EGFR和DEC1的表达。结果在癌组织中,EGFR胞膜上的表达为45.3%(34/75),DEC1胞核上的表达为54.7%(41/75),两者均与癌旁组织的表达有统计学差异(P<0.001);EGFR的表达与组织分化(P=0.033)、淋巴结转移(P=0.006)和远处转移(P=0.043)相关,DEC1与年龄(P=0.026)和肿瘤大小(P=0.047)相关。表达模式为EGFR+/DEC1+的肺腺癌患者比EGFR-/DEC1-的患者发生淋巴结转移的百分率高,两者有统计学差异(P=0.024)。结论 EGFR和DEC1蛋白的共表达可促进肺腺癌患者淋巴结转移。
Objective To investigate the expression of EGFR and DEC1 in lung adenocarcinoma and its relationship with clinical features. Methods Immunohistochemistry was used to detect the expression of EGFR and DEC1 in 75 cases of lung adenocarcinoma and adjacent normal tissues. Results The expression of EGFR on the membrane was 45.3% (34/75) in carcinoma and 54.7% (41/75) on the surface of DEC1, both of which were significantly different from that of adjacent tissues P <0.001). The expression of EGFR was correlated with differentiation (P = 0.033), lymph node metastasis (P = 0.006) and distant metastasis (P = 0.043) Related. The percentage of lymph node metastases in patients with lung adenocarcinoma expressing EGFR + / DEC1 + was significantly higher than that of patients with EGFR- / DEC1-, with a significant difference (P = 0.024). Conclusion The co-expression of EGFR and DEC1 protein can promote lymph node metastasis in patients with lung adenocarcinoma.